Niclosamide . ethanolamine

Product description: With slightly better solubility properties compared to Niclosamide (Prod. No. AG-CR1-3643). Antihelminthic, molluscicide and trypanocidal agent that inhibits mitochondrial oxidative phosphorylation and anaerobic ATP production. Anticancer agent with antiproliferative activity in a broad spectrum of cancer cells. Targets and inhibits multiple signaling pathways, including STAT3, NF-kB, Wnt/beta-catenin, Notch and mTORC1. Shown to block TNF-alpha-induced IkappaBalpha phosphorylation, translocation of p65 and the expression of NF-kappaB-regulated genes and elevates reactive oxygen species (ROS) levels. Promotes Frizzled1 internalization, down-regulates the expression of Dishevelled-2 protein and inhibits beta-catenin stabilization. Inhibits mTORC1 but not mTORC2 signaling in cells maintained in nutrient-rich conditions. Cell permeable selective STAT3 inhibitor (IC50=0.25µM). Inhibits the activation, nuclear translocation and transactivation of STAT3. Selective over STAT1, STAT5, JAK1, JAK2 and Src kinases. Induces cell cycle arrest, growth inhibition, autophagy and apoptosis. Inhibits S100A4 (Metastasin-1)-induced metastasis in vivo. Inhibits androgen receptor (AR) splice variants. Anti-inflammatory compound. Quorum sensing inhibitor. Broad-spectrum antiviral agent that targets acidified endosomes. Has been shown to inhibit replication of SARS and is a potential candidate to treat SARS-CoV-2 (COVID-19) infections. Antiobesity and antidiabetic agent. Positive allosteric neuropetide Y4 receptor ligand and increases energy expenditure and lipid metabolism through mitochondrial uncoupling.

Alternate Names/Synonyms: Niclosamide-olamine; Clonitralide; Bayluscide; BAY-6076; HL2448; Mollutox; 2',5-Dichloro-4'-nitro-salicylanilide 2-aminoethanol salt

CAS: 1420-04-8

Lien vers la Fiche Technique